Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02061748 · ClinicalTrials.gov registry record
The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 38,499
- Enrollment target
NCT02061748: Completed study, sponsored by Boehringer Ingelheim.
NCT02061748 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 38,499 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02061748 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 38,499 participants
- Enrollment target
Study Summary
This study is an opportunity for Boehringer Ingelheim to collaborate with Humana to conduct comparative safety and effectiveness studies of dabigatran and warfarin using real world data from Humana's health plan operations.
Primary Outcome
This outcome measure describes the incidence of stroke (hemorrhagic and ischemic) for dabigatran and warfarin in the primary analysis. Ischemic stroke includes: Occlusion and stenosis of precerebral arteries with cerebral infarction, Occlusion of cerebral arteries with cerebral infarction and Acute, but ill-defined, cerebrovascular disease but excludes above diagnosis if hospitalization lasted less than 48 hours and was accompanied by carotid endarterectomy. Hemorrhagic stroke includes: Subara
Interventions
- DRUG Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38,499 participants |
| Start Date | 2014-10-28 |
| Est. Completion | 2016-03-15 |
What the finished NCT02061748 record still lists
NCT02061748 is an observational study that tracks outcomes without assigning an intervention. Its 38,499 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Observational is the first listed.
NCT02061748 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02061748 about?
NCT02061748 is a clinical study titled "The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage". This study is an opportunity for Boehringer Ingelheim to collaborate with Humana to conduct comparative safety and effectiveness studies of dabigatran and warfarin using real world data from Humana's health plan operations.
What is the current status of trial NCT02061748?
This trial is currently completed. The enrollment target is 38,499 participants. The study started on 2014-10-28. Estimated completion is 2016-03-15.
What interventions are being tested in trial NCT02061748?
The interventions under investigation include: Observational (DRUG).
Who is sponsoring clinical trial NCT02061748?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796505 · 37,122 participants · NA
Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
- NCT04994756 · 40,000 participants
Stroke Thrombectomy and Aneurysm Registry
- NCT06768814 · 40,000 participants · NA
Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI